Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07658378

Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.

A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population.

Eligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Surgical Site Infection (SSI) Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Surgical Wound Infection Wound Infection

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cardiothoracic ICU-admitted patients who underwent CABG on CPB.

Exclusion criteria

  • Patients who require reoperation within 30 days.
  • Immunosuppressant patients.
  • Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
  • Pregnancy or breastfeeding.
  • Patients who refused to sign the informed consent.

Treatment and study plan

Cefazolin 2 g Infusion

Drug

To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

Cefazolin 2 GM Injection

Drug

To evaluate the effectiveness of intermittent (INT) cefazolin administration in preventing SSIs in a CABG (coronary artery bypass grafting) population.

Primary outcomes

  1. Incidence of SSI

    Time frame: Within 3 months after surgery

Study contacts

Contact information is provided by the study sponsor or research team.

Heba A Abdeen

CONTACT

[email protected]

0201003403231

Sponsors and collaborators

Lead sponsor

Helwan University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 22, 2026
Registry last updated
Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.